AVTX.US Avalo Therapeutics Inc

Healthcare Biotechnology USA Stocks
7.76 USD
Close of Nov 14, 2026
6.53 24.27
Market cap
USD 449M
P/E
-
P/B
1.02x
ROE
-22.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AVTX.US undervalued?

Graham number

The Graham number of Avalo Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Avalo Therapeutics Inc fundamental analysis

No fundamental analysis for Avalo Therapeutics Inc yet.

Avalo Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Avalo Therapeutics Inc

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporate…

Full company profile